Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

The antiviral cytokines IFN-α and IFN-β modulate parietal epithelial cells and promote podocyte loss: implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration.

Migliorini A, Angelotti ML, Mulay SR, Kulkarni OO, Demleitner J, Dietrich A, Sagrinati C, Ballerini L, Peired A, Shankland SJ, Liapis H, Romagnani P, Anders HJ.

Am J Pathol. 2013 Aug;183(2):431-40. doi: 10.1016/j.ajpath.2013.04.017. Epub 2013 Jun 5.

PMID:
23747509
2.

Podocyte loss involves MDM2-driven mitotic catastrophe.

Mulay SR, Thomasova D, Ryu M, Kulkarni OP, Migliorini A, Bruns H, Gröbmayr R, Lazzeri E, Lasagni L, Liapis H, Romagnani P, Anders HJ.

J Pathol. 2013 Jul;230(3):322-35. doi: 10.1002/path.4193.

PMID:
23749457
3.

Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders.

Lasagni L, Ballerini L, Angelotti ML, Parente E, Sagrinati C, Mazzinghi B, Peired A, Ronconi E, Becherucci F, Bani D, Gacci M, Carini M, Lazzeri E, Romagnani P.

Stem Cells. 2010 Sep;28(9):1674-85. doi: 10.1002/stem.492.

4.

Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy.

Zoja C, Garcia PB, Rota C, Conti S, Gagliardini E, Corna D, Zanchi C, Bigini P, Benigni A, Remuzzi G, Morigi M.

Am J Physiol Renal Physiol. 2012 Nov 1;303(9):F1370-81. doi: 10.1152/ajprenal.00057.2012. Epub 2012 Sep 5.

5.

Podocyte repopulation by renal progenitor cells following glucocorticoids treatment in experimental FSGS.

Zhang J, Pippin JW, Krofft RD, Naito S, Liu ZH, Shankland SJ.

Am J Physiol Renal Physiol. 2013 Jun 1;304(11):F1375-89. doi: 10.1152/ajprenal.00020.2013. Epub 2013 Mar 13.

6.

Podocyte mitosis - a catastrophe.

Lasagni L, Lazzeri E, Shankland SJ, Anders HJ, Romagnani P.

Curr Mol Med. 2013 Jan;13(1):13-23. Review.

7.

HIV-associated nephropathy: experimental models.

Avila-Casado C, Fortoul TI, Chugh SS.

Contrib Nephrol. 2011;169:270-85. doi: 10.1159/000320212. Epub 2011 Jan 20.

PMID:
21252526
8.

New insights into the pathology of podocyte loss: mitotic catastrophe.

Liapis H, Romagnani P, Anders HJ.

Am J Pathol. 2013 Nov;183(5):1364-74. doi: 10.1016/j.ajpath.2013.06.033. Epub 2013 Sep 3. Review.

9.

Interferon-gamma (IFN-gamma) and IL-4 expressed during mercury-induced membranous nephropathy are toxic for cultured podocytes.

Coers W, Vos JT, Van der Meide PH, Van der Horst ML, Huitema S, Weening JJ.

Clin Exp Immunol. 1995 Nov;102(2):297-307.

10.

Glomerular endothelial cell injury and damage precedes that of podocytes in adriamycin-induced nephropathy.

Sun YB, Qu X, Zhang X, Caruana G, Bertram JF, Li J.

PLoS One. 2013;8(1):e55027. doi: 10.1371/journal.pone.0055027. Epub 2013 Jan 24.

11.

Proteinuria impairs podocyte regeneration by sequestering retinoic acid.

Peired A, Angelotti ML, Ronconi E, la Marca G, Mazzinghi B, Sisti A, Lombardi D, Giocaliere E, Della Bona M, Villanelli F, Parente E, Ballerini L, Sagrinati C, Wanner N, Huber TB, Liapis H, Lazzeri E, Lasagni L, Romagnani P.

J Am Soc Nephrol. 2013 Nov;24(11):1756-68. doi: 10.1681/ASN.2012090950. Epub 2013 Aug 15.

12.

CDK inhibitor p21 is prosurvival in adriamycin-induced podocyte injury, in vitro and in vivo.

Marshall CB, Krofft RD, Pippin JW, Shankland SJ.

Am J Physiol Renal Physiol. 2010 May;298(5):F1140-51. doi: 10.1152/ajprenal.00216.2009. Epub 2010 Feb 3.

13.

Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria.

Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J.

J Am Soc Nephrol. 2005 Jun;16(6):1733-41. Epub 2005 Apr 13.

14.

Progenitor cells and podocyte regeneration.

Shankland SJ, Pippin JW, Duffield JS.

Semin Nephrol. 2014 Jul;34(4):418-28. doi: 10.1016/j.semnephrol.2014.06.008. Epub 2014 Jun 13. Review.

15.

Retinoic acid improves nephrotoxic serum-induced glomerulonephritis through activation of podocyte retinoic acid receptor α.

Dai Y, Chen A, Liu R, Gu L, Sharma S, Cai W, Salem F, Salant DJ, Pippin JW, Shankland SJ, Moeller MJ, Ghyselinck NB, Ding X, Chuang PY, Lee K, He JC.

Kidney Int. 2017 Jul 27. pii: S0085-2538(17)30321-6. doi: 10.1016/j.kint.2017.04.026. [Epub ahead of print]

PMID:
28756872
16.

β-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury.

Buelli S, Rosanò L, Gagliardini E, Corna D, Longaretti L, Pezzotta A, Perico L, Conti S, Rizzo P, Novelli R, Morigi M, Zoja C, Remuzzi G, Bagnato A, Benigni A.

J Am Soc Nephrol. 2014 Mar;25(3):523-33. doi: 10.1681/ASN.2013040362. Epub 2013 Dec 26.

17.

Expression of CCN1 (CYR61) in developing, normal, and diseased human kidney.

Sawai K, Mukoyama M, Mori K, Kasahara M, Koshikawa M, Yokoi H, Yoshioka T, Ogawa Y, Sugawara A, Nishiyama H, Yamada S, Kuwahara T, Saleem MA, Shiota K, Ogawa O, Miyazato M, Kangawa K, Nakao K.

Am J Physiol Renal Physiol. 2007 Oct;293(4):F1363-72. Epub 2007 Aug 15.

18.

Retinoids augment the expression of podocyte proteins by glomerular parietal epithelial cells in experimental glomerular disease.

Zhang J, Pippin JW, Vaughan MR, Krofft RD, Taniguchi Y, Romagnani P, Nelson PJ, Liu ZH, Shankland SJ.

Nephron Exp Nephrol. 2012;121(1-2):e23-37. doi: 10.1159/000342808. Epub 2012 Oct 25.

19.

Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis.

Patek CE, Fleming S, Miles CG, Bellamy CO, Ladomery M, Spraggon L, Mullins J, Hastie ND, Hooper ML.

Hum Mol Genet. 2003 Sep 15;12(18):2379-94. Epub 2003 Jul 22.

PMID:
12915483
20.

Unraveling the role of podocyte turnover in glomerular aging and injury.

Wanner N, Hartleben B, Herbach N, Goedel M, Stickel N, Zeiser R, Walz G, Moeller MJ, Grahammer F, Huber TB.

J Am Soc Nephrol. 2014 Apr;25(4):707-16. doi: 10.1681/ASN.2013050452. Epub 2014 Jan 9.

Supplemental Content

Support Center